NeoImmuneTech, Genexine, SNUH and POSTECH researchers Announce Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019

April 3, 2019 Off By BusinessWire

Data presented includes results from preclinical studies and clinical
trials with the T cell amplifier Hyleukin-7™

ROCKVILLE, Md.–(BUSINESS WIRE)–NeoImmuneTech,
Inc.
(NIT), a T cell-based therapeutics company, today announced the
presentation of new research at the AACR Annual Meeting, being held
March 29 – April 3, 2019 in Atlanta, GA. Study results regarding
Hyleukin-7™ (Interleukin-7-hyFc), developed jointly with Korean
affiliate company Genexine, Inc. (Genexine), will be presented in two
posters.

Presentation Details:

Title: CT045. Hyleukin-7, a long-acting interleukin-7, increased
absolute lymphocyte counts after subcutaneous and intramuscular
administration in healthy subjects
Date: April 1, 2019

This poster details Hyleukin-7’s safety profile and T cell boosting
effects from the first-in-human study in healthy subjects. Hyleukin-7
administration was well-tolerated, exhibited dose-dependent increases in
T cells, and significantly increased killer and memory T cells, which
are crucial for effective anti-tumor response. Additionally, the poster
reports that dose escalation of Hyleukin-7 in multiple ongoing clinical
trials in cancer patients has shown similar safety profiles to the
first-in-human study, and also demonstrated dose-dependent increases of
killer T cells. The study was led by professor Howard Lee of Seoul
National University Hospital (SNUH).

Title: 4991. Hyleukin-7, the Fc-fused interleukin-7, generates
anti-tumor activity by modulating both adaptive and innate immune cells
in the tumor microenvironment
Date: April 3, 2019

Data shown here focuses on the anti-cancer mechanism of Hyleukin-7 from
preclinical studies. Hyleukin-7 affected the immune cells not
only in the peripheral blood but also in the tumor microenvironment
(TME). This study, led by professor Seung-Woo Lee of Pohang University
of Science and Technology (POSTECH), Korea, demonstrated that
administration of Hyleukin-7 in an animal cancer model significantly
increased the quantity of killer T cells. Most importantly, within the
TME killer T cells drastically increased while regulatory T cells and
myeloid lineage cells (immune suppressor cells) such as myeloid-derived
suppressor cells (MDSC) substantially decreased, resulting in
significant anti-tumor activity.

This research is the first to demonstrate that a long-acting IL-7
effectively modulates the TME, significantly amplifying anti-tumor T
cells and reducing immune-suppressive cells such as MDSCs in the tumor,”
said professor Seung-Woo Lee. “These data allow us to envision
Hyleukin-7 as a potential next-generation cancer immunotherapy with a
differentiated function.”

Having recently raised $92 million in Series D funding round, we aim to
use the funds to continue confirming the anti-tumor effects and mode of
action of Hyleukin-7 through multiple monotherapy and combination
therapy clinical trials in various tumor types,” added Se Hwan Yang,
Ph.D., Chief Executive Officer of NIT.

NIT and Genexine are currently conducting dose-escalation studies to
identify an optimal Hyleukin-7 dosing regimen in advanced solid tumors
and brain cancer (glioblastoma) patients. NIT and Genexine are also
collaborating with global pharmaceutical companies to combine Hyleukin-7
with anti-PD-1/anti-PD-L1 therapies in clinical trials in high-risk skin
cancers and triple-negative breast cancer patients in the United States
and Korea, respectively.

About Hyleukin-7™
Hyleukin-7™ (rhIL-7-hyFc,
NT-I7), an immuno-oncology agent, is a T cell growth factor composed of
a covalently linked homodimer of engineered Interleukin-7 (IL-7)
molecule, biologically fused with the proprietary long-acting platform –
hyFc™. IL-7 is known to be a critical factor for T cells homeostasis,
acting to increase both the number and functionality of T cells.
Hyleukin-7 amplifies and reinvigorates persistent T cell immunity in the
treatment of patients with cancer and lymphopenia, thus providing unique
opportunities for immuno-oncology (IO) combination strategies.
Hyleukin-7 is being developed as an “IO enabling” therapy to harness T
cell immunity in combination with current cancer treatments such as
anti-PD-(L)1 agents or chemo/radiotherapy as well as next generation IO
therapeutics.

About NeoImmuneTech, Inc.
NeoImmuneTech (NIT) is developing
T cell-based therapeutics designed to prime, enhance and extend the
activity of current and future cancer therapies. Our lead product,
Hyleukin-7™, a T cell growth factor, amplifies and reinvigorates
persistent anti-tumor activity, which is pivotal to extending survival
of cancer patients. Hyleukin-7 is being studied in multiple clinical
trials in solid tumors, and being planned for testing in hematologic
malignancies, additional solid tumors and other immunology-focused
indications. www.neoimmunetech.com
NIT
is a U.S.-based company developing Hyleukin-7 for the U.S. and EU
markets in collaboration with Korean-based Genexine.

Contacts

MacDougall
Shai Biran, Ph.D.
+1 781-235-3060
[email protected]